Company news

Adagene, Inc. news in 2026

Adagene, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer

October 28, 2026

Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

October 27, 2026

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

April 2, 2026

Decks in 2026